{"cdcTestId":"2020-0026","testcaseName":"Dose #2 of Pfizer Covid-19 Vaccine at 21 - 4 days (age 5 years). Forecast booster","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"2017-09-28T00:00:00","gender":"M"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-09-28T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"218","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-15T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"218","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-12-10T00:00:00","recommendedDate":"2022-12-10T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-09-28T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"218","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-15T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"218","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-10-19T12:12:35.238","generalDescription":"This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 - 4 days after the first dose that the dose is valid. Another dose should be forecast.","changedInVersion":"4.28","reasonForChange":"v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.\nv4.23 Updated the test case based on new updated ACIP Guideline Recommendations (05/19/22) that expands the eligibility for a booster dose for children ages 5-11 years, 5 months after the second dose.\nv4.14 Updated the test case based on new updated ACIP Guideline Recommendations (11/3/2021).  Updated test case name, age, and description from 12 to 5 years. Updated CVX Code to 218.\nv4.12 Updated per ACIP recommendations, on 09/22/2021, for Pfizer Covid-19 booster dose. \nv4.8 Changed age of patient from 16 to 12 years based on new ACIP guidelines for Pfizer vaccine eligibility."}